Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Novo Nordisk shares are experiencing a significant decline amidst intensified investor concerns over its competitiveness in ...

Amy Schumer has opened up about her current health journey, revealing that she’s seeing strong results using the weight loss ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

The exorbitant costs of drugs like Wegovy — especially compared to other countries — have prompted some insurers to tighten ...

GEMMA Collins has today revealed the horrifyingly cruel nickname she was called before going on fat jabs. The TV favourite, ...

Schumer said she was having success on Mounjaro after previously being unable to "handle" Ozempic's side effects.

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

JM Financial is bullish on Mounjaro's success in India, citing its price advantage, higher efficiency and the country's large ...

The popularity of Novo Nordisk's Ozempic and Wegovy has attracted competitors and created supply constraints. Novo Nordisk's next-generation weight loss drug disappointed investors in Phase III ...

GLP-1 drugs such as Wegovy, Ozempic, Zepbound and Mounjaro have helped millions of people combat type 2 diabetes and ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...